Corrigenda - Postmortem Brain: An Underutilized Substrate for Studying Severe Mental Illness (Neuropsychopharmacology Reviews (2014) 39, (65-87) DOI: 10.1038/npp.2013.239);Postmortem brain: An underutilized substrate for studying severe mental illness

Neuropsychopharmacology

Volumn 39, Issue 1, 2014, Pages 65-87

  Mccullumsmith, Robert E ^a   Hammond, John H ^b   Shan, Dan ^b   Meador Woodruff, James H ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

fractionation; immunoisolation; PCR; postmortem; schizophrenia; western blot

Indexed keywords

GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; NEU DIFFERENTIATION FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; PROTEIN A; SYNTAXIN; VESICULAR GLUTAMATE TRANSPORTER;

AUTOPSY; BRAIN TISSUE; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; HEMISPHERIC DOMINANCE; HIPPOCAMPUS; HUMAN; NONHUMAN; PALMITOYLATION; PHENOTYPE; POSTMORTEM CHANGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA; UBIQUITINATION; ANIMAL; BIOLOGICAL MODEL; BRAIN; DISEASE MODEL; METABOLISM; UTILIZATION;

ANIMALS; AUTOPSY; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MODELS, NEUROLOGICAL; SCHIZOPHRENIA;

EID: 84890491302     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.337     Document Type: Erratum

References (276)

1. Abekawa T, Ito K, Nakagawa S, Nakato Y, Koyama T (2008). Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex. Schizophr Res 101: 84-94
2. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP et al. (1996). Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16: 19-30
3. Akil M, Edgar CL, Pierri JN, Casali S, Lewis DA (2000). Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry 47: 361-370
4. Alda M, Ahrens B, Lit W, Dvorakova M, Labelle A, Zvolsky P et al. (1996). Age of onset in familial and sporadic schizophrenia. Acta Psychiatr Scand 93: 447-450
5. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y et al. (2005). Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 58: 85-96
6. Amar S, Shaltiel G, Mann L, Shamir A, Dean B, Scarr E et al. (2008). Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Int J Neuropsychopharmacol 11: 197-205
7. Ashby M, De La Rue S, Ralph G, Uney J, Collingridge G, Henley J (2004). Removal of AMPA receptors (AMPARs) from synapses is preceded by transient endocytosis of extrasynaptic AMPARs. J Neurosci 24: 5172-5176
8. Atkin T, Kittler J (2012). DISC1 and the aggresome: A disruption to cellular functioñAutophagy 8: 851-852
9. Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N et al. (2011). An integrated in vitro and in vivo high-Throughput screen identifies treatment leads for ependymoma. Cancer Cell 20: 384-399
10. Badcock JC (2010). The cognitive neuropsychology of auditory hallucinations: A parallel auditory pathways framework. Schizophr Bull 36: 576-584
11. Badner JA, Gershon ES (2002). Meta-Analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 7: 405-411
12. Bahn S, Augood SJ, Ryan M, Standaert DG, Starkey M, Emson PC (2001). Gene expression profiling in the post-mortem human brain-no cause for dismay. J Chem Neuroanat 22: 79-94
13. Balu DT, Coyle JT (2011). Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev 35: 848-870
14. Bannerman DM, Deacon RM, Brady S, Bruce A, Sprengel R, Seeburg PH et al. (2004). A comparison of GluR-A-deficient and wild-Type mice on a test battery assessing sensorimotor, affective, and cognitive behaviors. Behav Neurosci 118: 643-647
15. Barakauskas VE, Beasley CL, Barr AM, Ypsilanti AR, Li HY, Thornton AE et al. (2010). A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia. Neuropsychopharmacology 35: 1226-1238
16. Barnes EM Jr. (2000). Intracellular trafficking of GABA(A) receptors. Life Sci 66: 1063-1070
17. Barton AJ, Pearson RC, Najlerahim A, Harrison PJ (1993). Pre-And postmortem influences on brain RNA. J Neurochem 61: 1-11
18. Basil B, Adetunji B, Mathews M, Budur K (2006). Trial of risperidone in India-concerns. Br J Psychiatry 188: 489-490
19. Bats C, Groc L, Choquet D (2007). The interaction between Stargazin and PSD-95 regulates AMPA receptor surface trafficking. Neuron 53: 719-734
20. Bauer D, Haroutunian V, McCullumsmith R, Meador-Woodruff J (2009). Expression of four housekeeping proteins in elderly patients with schizophrenia. J Neural Transm 116: 487-491
21. Bauer D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE (2010). Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr Res 117: 92-98
22. Bauer D, McCullumsmith RE, Meador-Woodruff JH (2008). A role for glutamate receptors, transporters, and interacting proteins in cortical dysfunction in schizophrenia. P. O'Donnell (eds) Cortical Deficits in Schizophrenia: From Genes to Function. Springer Science Business Media, LLC: New York, NY, USA, pp 113-148
23. Beckstrøm H, Julsrud L, Haugeto Ø, Dewar D, Graham DI, Lehre KP et al. (1999). Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease. J Neurosci Res 55: 218-229
24. Bedoukian M, Weeks A, Partin K (2006). Different domains of the AMPA receptor direct stargazin-mediated trafficking and stargazin-mediated modulation of kinetics. J Biol Chem 281: 23908-23921
25. Beerpoot LJ, Lipska BK, Weinberger DR (1996). Neurobiology of treatmentresistant schizophrenia: New insights and new models. Eur Neuropsychopharmacol 6(Suppl 2): S27-S34
26. Behan AT, Byrne C, Dunn MJ, Cagney G, Cotter DR (2009). Proteomic analysis of membrane microdomain-Associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry 14: 601-613
27. Bendall SC, Simonds EF, Qiu P, Amir el-AD, Krutzik PO, Finck R et al. (2011). Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332: 687-696
28. Beneyto M, Meador-Woodruff JH (2008). Lamina-specific abnormalities of NMDA receptor-Associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33: 2175-2186
29. Bennett BM, Reynolds JN, Prusky GT, Douglas RM, Sutherland RJ, Thatcher GR (2007). Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester. Neuropsychopharmacology 32: 505-513
30. Bhugra D (2005). The global prevalence of schizophrenia. PLoS Med 2: E151
31. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ (2001). Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: Clinical and P300 findings in a family. Am J Hum Genet 69: 428-433
32. Blandini F (2010). An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct Neurol 25: 65-71
33. Bodenmiller B, Zunder ER, Finck R, Chen TJ, Savig ES, Bruggner RV et al. (2012). Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol 30: 858-867
34. Borrell J, Vela JM, Arevalo-Martin A, Molina-Holgado E, Guaza C (2002). Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 26: 204-215
35. Bousman CA, Chana G, Glatt SJ, Chandler SD, Lucero GR, Tatro E et al. (2010). Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: Convergent pathway analysis findings from two independent samples. Am J Med Genet B Neuropsychiatr Genet 153B: 494-502
36. Bousman CA, Chana G, Glatt SJ, Chandler SD, May T, Lohr J et al. (2010). Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood. Am J Med Genet B Neuropsychiatr Genet 153B: 1336-1341
37. Braithwaite SP, Xia H, Malenka RC (2002). Differential roles for NSF and GRIP/ABP in AMPA receptor cycling. Proc Natl Acad Sci USA 99: 7096-7101
38. Breese CR, Freedman R, Leonard SS (1995). Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Research 674: 82-90
39. Broadbelt K, Jones LB (2008). Evidence of altered calmodulin immunoreactivity in areas 9 and 32 of schizophrenic prefrontal cortex. J Psychiatr Res 42: 612-621
40. Bruder GE (1983). Cerebral laterality and psychopathology: A review of dichotic listening studies. Schizophr Bull 9: 134-151
41. Bubber P, Tang J, Haroutunian V, Xu H, Davis KL, Blass JP et al. (2004). Mitochondrial enzymes in schizophrenia. J Mol Neurosci 24: 315-321
42. Buchanan RW, Carpenter WT (2000). Schizophrenia: Introduction and overview. In: Sadock BJ, Sadock VA (eds). Comprehensive Textbook of Psychiatry, Vol 1 Lippincott, Williams, and Wilkins: Philadelphia, PA, USA, pp 1096-1110
43. Burnet PW, Eastwood SL, Harrison PJ (1997). [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: A comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30: 565-574
44. Butterworth J, Yates CM, Reynolds GP (1985). Distribution of phosphate-Activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and g-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J Neurol Sci 67: 161-171
45. Cai C, Coleman SK, Niemi K, Keinä nen K (2002). Selective binding of synapseassociated protein 97 to GluR-A alpha-Amino-5-hydroxy-3-methyl-4- isoxazole propionate receptor subunit is determined by a novel sequence motif. J Biol Chem 277: 31484-31490
46. Cai C, Li H, Rivera C, Keinä nen K (2006). Interaction between SAP97 and PSD-95, two Maguk proteins involved in synaptic trafficking of AMPA receptors. J Biol Chem 281: 4267-4273
47. Cain DF, Kappy MS (1971). Post mortem changes in extractable protein and in tissue pH in the guinea pig brain. J Neurochem 18: 115-121
48. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR et al. (2005). Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA 102: 8627-8632
49. Cao M, Xu J, Shen C, Kam C, Huganir R, Xia J (2007). PICK1-ICA69 heteromeric BAR domain complex regulates synaptic targeting and surface expression of AMPA receptors. J Neurosci 27: 12945-12956
50. Carlin RK, Grab DJ, Cohen RS, Siekevitz P (1980). Isolation and characterization of postsynaptic densities from various brain regions: Enrichment of different types of postsynaptic densities. J Cell Biol 86: 831-845
51. Carter MD, Weaver DF, Joudrey HR, Carter AO, Rockwood K (2007). Epilepsy and antiepileptic drug use in elderly people as risk factors for dementia. J Neurol Sci 252: 169-172
52. Carty NC, Xu J, Kurup P, Brouillette J, Goebel-Goody SM, Austin DR et al. (2012). The tyrosine phosphatase STEP: Implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Transl Psychiatry 2: E137
53. Castensson A, Emilsson L, Preece P, Jazin EE (2000). High-resolution quantification of specific mRNA levels in human brain autopsies and biopsies. Genome Res 10: 1219-1229
54. Castillo MA, Ghose S, Tamminga CA, Ulery-Reynolds PG (2010). Deficits in syntaxin 1 phosphorylation in schizophrenia prefrontal cortex. Biol Psychiatry 67: 208-216
55. Chakirova G, Whalley HC, Thomson PA, Hennah W, Moorhead TW, Welch KA et al. (2011). The effects of DISC1 risk variants on brain activation in controls, patients with bipolar disorder and patients with schizophrenia. Psychiatry Res 192: 20-28
56. Chandana R, Mythri RB, Mahadevan A, Shankar SK, Srinivas Bharath MM (2009). Biochemical analysis of protein stability in human brain collected at different post-mortem intervals. Indian J Med Res 129: 189-199
57. Chen L, Chetkovich D, Petralia R, Sweeney N, Kawasaki Y, Wenthold R et al. (2000). Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature 408: 936-943
58. Chen Y, Hancock ML, Role LW, Talmage DA (2010). Intramembranous valine linked to schizophrenia is required for neuregulin 1 regulation of the morphological development of cortical neurons. J Neurosci 30: 9199-9208
59. Cheng MC, Lu CL, Luu SU, Tsai HM, Hsu SH, Chen TT et al. (2010). Genetic and functional analysis of the DLG4 gene encoding the post-synaptic density protein 95 in schizophrenia. PLoS One 5: E15107
60. Chiba S, Hashimoto R, Hattori S, Yohda M, Lipska B, Weinberger DR et al. (2006). Effect of antipsychotic drugs on DISC1 and dysbindin expression in mouse frontal cortex and hippocampus. J Neural Trans 113: 1337-1346
61. Chubb JE, Bradshaw NJ, Soares DC, Porteous DJ, Millar JK (2008). The DISC locus in psychiatric illness. Mol Psychiatry 13: 36-64
62. Citri A, Malenka RC (2008). Synaptic plasticity: Multiple forms, functions, and mechanisms. Neuropsychopharmacology 33: 18-41
63. Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH (2003). Altered transcript expression of NMDA receptor-Associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry 160: 1100-1109
64. Clinton SM, Haroutunian V, Meador-Woodruff JH (2006). Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia. J Neurochem 98: 1114-1125
65. Clinton SM, Meador-Woodruff JH (2004). Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamus in Schizophrenia and Bipolar Disorder. Neuropsychopharmacology 29: 1353-1362
66. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT et al. (2011). Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 478: 519-523
67. Contractor A, Heinemann SF (2002). Glutamate receptor trafficking in synaptic plasticity. Sci STKE 2002: Re14
68. Czudek C, Reynolds GP (1990). [3H]nipecotic acid binding to gamma-Aminobutyric acid uptake sites in postmortem human brain. J Neurochem 55: 165-168
69. Dean B, Crossland N, Boer S, Scarr E (2008). Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. Schizophr Res 104: 185-197
70. Dejaegere T, Serneels L, Schafer MK, Van Biervliet J, Horre K, Depboylu C et al. (2008). Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. Proc Natl Acad Sci USA 105: 9775-9780
71. Delfs JM, Anegawa NJ, Chesselet MF (1995). Glutamate decarboxylase messenger RNA in rat pallidum: Comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments. Neuroscience 66: 67-80
72. Delotterie D, Ruiz G, Brocard J, Schweitzer A, Roucard C, Roche Y et al. (2010). Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. Psychopharmacology 208: 131-141
73. Desbonnet L, Waddington JL, O'Tuathaigh CM (2009). Mutant models for genes associated with schizophrenia. Biochem Soc Trans 37: 308-312
74. Devon RS, Anderson S, Teague PW, Burgess P, Kipari TM, Semple CA et al. (2001). Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorder. Psychiatr Genet 11: 71-78
75. Doerr A (2011). A flow cytometry revolution. Nat Methods 8: 531
76. Dong H, O'Brien R, Fung E, Lanahan A, Worley P, Huganir R (1997). GRIP: A synaptic PDZ domain-containing protein that interacts with AMPA receptors. Nature 386: 279-284
77. Dorph-Petersen KA, Caric D, Saghafi R, Zhang W, Sampson AR, Lewis DA (2009). Volume and neuron number of the lateral geniculate nucleus in schizophrenia and mood disorders. Acta Neuropathol 117: 369-384
78. Dracheva S, Byne W, Chin B, Haroutunian V (2008). Ionotropic glutamate receptor mRNA expression in the human thalamus: Absence of change in schizophrenia. Brain Res 1214: 23-34
79. Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, Haroutunian V (2001). N-methyl-D-Aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158: 1400-1410
80. Dracheva S, McGurk S, Haroutunian V (2005). mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J Neurosci Res 79: 868-878
81. Drisdel RC, Green WN (2004). Labeling and quantifying sites of protein palmitoylation. Biotechniques 36: 276-285
82. Durrenberger PF, Fernando S, Kashefi SN, Ferrer I, Hauw JJ, Seilhean D et al. (2010). Effects of antemortem and postmortem variables on human brain mRNA quality: A BrainNet Europe study. J Neuropathol Exp Neurol 69: 70-81
83. Dwivedi Y, Mondal AC, Rizavi HS, Conley RR (2005). Suicide Brain Is Associated with Decreased Expression of Neurotrophins. Biological Psychiatry 58: 315-324
84. Dyck BA, Skoblenick KJ, Castellano JM, Ki K, Thomas N, Mishra RK (2009). Behavioral abnormalities in synapsin II knockout mice implicate a causal factor in schizophrenia. Synapse 63: 662-672
85. Eastwood SL, Harrison PJ (2001). Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull 55: 569-578
86. Eastwood SL, Harrison PJ (2005). Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: Further evidence for a synaptic pathology affecting glutamate neurons. Schizophr Res 73: 159-172
87. Eastwood SL, Walker M, Hyde TM, Kleinman JE, Harrison PJ (2010). The DISC1 Ser704Cys substitution affects centrosomal localization of its binding partner PCM1 in glia in human brain. Hum Mol Genet 19: 2487-2496
88. Eggan K (2008). Using stem cells and reprogramming to understand disease. Regen Med 3: 799-801
89. Eggan SM, Hashimoto T, Lewis DA (2008). Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 65: 772-784
90. Emamian ES, Karayiorgou M, Gogos JA (2004). Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia. J Neurosci 24: 1561-1564
91. English JA, Dicker P, Focking M, Dunn MJ, Cotter DR (2009). 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 9: 3368-3382
92. English JA, Pennington K, Dunn MJ, Cotter DR (2011). The neuroproteomics of schizophrenia. Biol Psychiatry 69: 163-172
93. Ervin JF, Heinzen EL, Cronin KD, Goldstein D, Szymanski MH, Burke JR et al. (2007). Postmortem delay has minimal effect on brain RNA integrity. J Neuropathol Exp Neurol 66: 1093-1099
94. Fanous AH, Zhou B, Aggen SH, Bergen SE, Amdur RL, Duan J et al. (2012). Genome-wide association study of clinical dimensions of schizophrenia: Polygenic effect on disorganized symptoms. Am J Psychiatry 169: 1309-1317
95. Fanselow MS, Dong HW (2010). Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 65: 7-19
96. Featherstone RE, Rizos Z, Nobrega JN, Kapur S, Fletcher PJ (2007). Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: Parallels to schizophrenia. Neuropsychopharmacology 32: 483-492
97. Feng Y, Thiagarajan PS, Ma PC (2012). MET signaling: Novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 7: 459-467
98. Fernandez E, Collins MO, Uren RT, Kopanitsa MV, Komiyama NH, Croning MD et al. (2009). Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins. Mol Syst Biol 5: 269
99. Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S et al. (2007). Brain protein preservation largely depends on the postmortem storage temperature: Implications for study of proteins in human neurologic diseases and management of brain banks: A BrainNet Europe Study. J Neuropathol Exp Neurol 66: 35-46
100. Fleige S, Pfaffl MW (2006). RNA integrity and the effect on the real-Time qRT-PCR performance. Mol Aspects Med 27: 126-139
101. Fountoulakis M, Hardmeier R, Hoger H, Lubec G (2001). Postmortem changes in the level of brain proteins. Exp Neurol 167: 86-94
102. Fredriksson S, Gullberg M, Jarvius J, Olsson C, Pietras K, Gustafsdottir SM et al. (2002). Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol 20: 473-477
103. Freyberg Z, Ferrando SJ, Javitch JA (2010). Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 167: 388-396
104. Funk A, Rumbaugh G, Harotunian V, McCullumsmith R, Meador-Woodruff J (2009). Decreased expression of NMDA receptor-Associated proteins in frontal cortex of elderly patients with schizophrenia. Neuroreport 20: 1019-1022
105. Funk AJ, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH (2012). Abnormal activity of the MAPK-And cAMP-Associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. Neuropsychopharmacology 37: 896-905
106. Geddes AE, Huang X-F, Newell KA (2011). Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 35: 896-904
107. Gershon ES, Alliey-Rodriguez N, Liu C (2011). After GWAS: Searching for genetic risk for schizophrenia and bipolar disorder. Am J Psychiatry 168: 253-256
108. Gilmore JH, Lawler CP, Eaton AM, Mailman RB (1993). Postmortem stability of dopamine D1 receptor mRNA and D1 receptors. Brain Res Mol Brain Res 18: 290-296
109. Glantz LA, Lewis DA (1997). Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch Gen Psychiatry 54: 943-952
110. Goff D, Lamberti J, Leon A, Green M, Miller A, Patel J et al. (2008). A placebocontrolled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 33: 465-472
111. Golub MS, Germann SL, Lloyd KC (2004). Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behav Brain Res 153: 159-170
112. Gonzalez-Maeso J, Torre I, Rodriguez-Puertas R, Garcia-Sevilla JA, Guimon J, Meana JJ (2002). Effects of age, postmortem delay and storage time on receptor-mediated activation of G-proteins in human brain. Neuropsychopharmacology 26: 468-478
113. Gullberg M, Gustafsdottir SM, Schallmeiner E, Jarvius J, Bjarnegard M, Betsholtz C et al. (2004). Cytokine detection by antibody-based proximity ligation. Proc Natl Acad Sci USA 101: 8420-8424
114. Guo X, Hamilton P, Reish N, Sweatt J, Miller C, Rumbaugh G (2009). Reduced Expression of the NMDA Receptor-Interacting Protein SynGAP Causes Behavioral Abnormalities that Model Symptoms of Schizophrenia. Neuropsychopharmacology 34: 1659-1672
115. Hahn CG, Banerjee A, Macdonald ML, Cho DS, Kamins J, Nie Z et al. (2009). The post-synaptic density of human postmortem brain tissues: An experimental study paradigm for neuropsychiatric illnesses. PLoS One 4: E5251 Develops a novel approach to isolate and characterize PSDs in postmortem brain
116. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH et al. (2006). Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12: 824-828
117. Haller J, Szirmai M, Varga B, Ledent C, Freund TF (2005). Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav Pharmacol 16: 415-422
118. Hammond J, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH (2011). Endosomal trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Schizophr Res 130: 260-265
119. Hammond JC, McCullumsmith RE, Funk AJ, Haroutunian V, Meador-Woodruff JH (2010). Evidence for abnormal forward trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Neuropsychopharmacology 35: 2110-2119
120. Hammond JC, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH (2011). Endosomal trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Schizophr Res 130: 260-265
121. Hammond JC, Meador-Woodruff JH, Haroutunian V, McCullumsmith RE (2012). AMPA receptor subunit expression in the endoplasmic reticulum in frontal cortex of elderly patients with schizophrenia. PLoS One 7: E39190
122. Hanlon FM, Sutherland RJ (2000). Changes in adult brain and behavior caused by neonatal limbic damage: Implications for the etiology of schizophrenia. Behav Brain Res 107: 71-83
123. Hardy JA, Wester P, Winblad B, Gezelius C, Bring G, Eriksson A (1985). The patients dying after long terminal phase have acidotic brains; implications for biochemical measurements on autopsy tissue. J Neural Transm 61: 253-264
124. Haroutunian V, Katsel P, Dracheva S, Davis KL (2006). The human homolog of the QKI gene affected in the severe dysmyelination "quaking" mouse phenotype: Downregulated in multiple brain regions in schizophrenia. Am J Psychiatry 163: 1834-1837
125. Harrison PJ, Heath PR, Eastwood SL, Burnet PW, McDonald B, Pearson RC (1995). The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: Selective mRNA vulnerability and comparison with their encoded proteins. Neurosci Lett 200: 151-154
126. Harrison PJ, Procter AW, Barton AJ, Lowe SL, Najlerahim A, Bertolucci PH et al. (1991). Terminal coma affects messenger RNA detection in post mortem human temporal cortex. Brain Res Mol Brain Res 9: 161-164
127. Hasler G, Drevets WC, Manji HK, Charney DS (2004). Discovering endophenotypes for major depression. Neuropsychopharmacology 29: 1765-1781
128. Haupt A, Joberty G, Bantscheff M, Frohlich H, Stehr H, Schweiger MR et al. (2012). Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-Targeted chemoproteomics. BMC Cancer 12: 38
129. Hazlett EA, Speiser LJ, Goodman M, Roy M, Carrizal M, Wynn JK et al. (2007). Exaggerated affect-modulated startle during unpleasant stimuli in borderline personality disorder. Biol Psychiatry 62: 250-255
130. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S et al. (2007). Dominant-negative DISC1 transgenic mice display schizophrenia-Associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA 104: 14501-14506
131. Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R (2009). Peptide microarrays for detailed, high-Throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A. Anal Biochem 387: 150-161
132. Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH et al. (2004). Disrupted in schizophrenia 1 (DISC1): Association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 75: 862-872
133. Holmseth S, Dehnes Y, Huang YH, Follin-Arbelet VV, Grutle NJ, Mylonakou MN et al. (2012). The density of EAAC1 (EAAT3) glutamate transporters expressed by neurons in the mammalian CNS. J Neurosci 32: 6000-6013
134. Huang H-S, Matevossian A, Jiang Y, Akbarian S (2006). Chromatin immunoprecipitation in postmortem brain. J Neurosci Methods 156: 284-292
135. Huerta I, McCullumsmith RE, Haroutunian V, Gimenez-Amaya JM, Meador-Woodruff JH (2006). Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia. Synapse 59: 394-402
136. Huotari M, Garcia-Horsman JA, Karayiorgou M, Gogos JA, Mannisto PT (2004). D-Amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl) 172: 1-10
137. Ibarra C, Nedvetsky PI, Gerlach M, Riederer P, Schmidt HHHW (2001). Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain. Brain Res 907: 54-60
138. Ide M, Ohnishi T, Murayama M, Matsumoto I, Yamada K, Iwayama Y et al. (2006). Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia. J Neurochem 99: 277-287
139. Jaffrey SR (2005). Detection and characterization of protein nitrosothiols. Methods Enzymol 396: 105-118
140. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH (2001). Protein S-nitrosylation: A physiological signal for neuronal nitric oxide. Nat Cell Biol 3: 193-197
141. Jaffrey SR, Snyder SH (2001). The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE 2001: Pl1
142. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225
143. Jin W, Ge W, Xu J, Cao M, Peng L, Yung W et al. (2006). Lipid binding regulates synaptic targeting of PICK1, AMPA receptor trafficking, and synaptic plasticity. J Neurosci 26: 2380-2390
144. Johnston NL, Cervenak J, Shore AD, Torrey EF, Yolken RH (1997). Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR. Stanley Neuropathology Consortium. J Neurosci Methods 77: 83-92
145. Joyce JN, Meador-Woodruff JH (1997). Linking the family of D2 receptors to neuronal circuits in human brain: Insights into schizophrenia. Neuropsychopharmacology 16: 375-384
146. Kamiya A, Sedlak TW, Pletnikov MV (2012). DISC1 pathway in brain development: Exploring therapeutic targets for major psychiatric disorders. Front Psychiatry 3: 25
147. Kang R, Wan J, Arstikaitis P, Takahashi H, Huang K, Bailey AO et al. (2008). Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. Nature 456: 904-909
148. Kato T, Kasai A, Mizuno M, Fengyi L, Shintani N, Maeda S et al. (2010). Phenotypic characterization of transgenic mice overexpressing Neuregulin-1. PLoS One 5: E14185
149. Kay SR (1990). Significance of the positive-negative distinction in schizophrenia. Schizophr Bull 16: 635-652
150. Kim MJ, Futai K, Jo J, Hayashi Y, Cho K, Sheng M (2007). Synaptic accumulation of PSD-95 and synaptic function regulated by phosphorylation of serine-295 of PSD-95. Neuron 56: 488-502
151. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ et al. (1995). Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res 28: 311-318
152. Knapp M, Mangalore R, Simon J (2004). The global costs of schizophrenia. Schizophr Bull 30: 279-293
153. Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR et al. (2008). Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry 63: 759-765
154. Kozlovsky N, Belmaker RH, Agam G (2001). Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res 52: 101-105
155. Kristiansen L, Beneyto M, Haroutunian V, Meador-Woodruff J (2006). Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 11: 737-747, 705
156. Kristiansen L, Patel S, Haroutunian V, Meador-Woodruff J (2010). Expression of the NR2B-NMDA receptor subunit and its Tbr-1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia. Synapse 64: 495-502
157. Kristiansen LV, Meador-Woodruff JH (2005). Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 78: 87-93
158. Kunii Y, Ikemoto K, Wada A, Yang Q, Kusakabe T, Suzuki T et al. (2011). Detailed DARPP-32 expression profiles in postmortem brains from patients with schizophrenia: An immunohistochemical study. Med Mol Morphol 44: 190-199
159. Kunii Y, Yabe H, Wada A, Yang Q, Nishiura K, Niwa S (2011). Altered DARPP-32 expression in the superior temporal gyrus in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35: 1139-1143
160. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999). Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 46: 56-72
161. Lau CG, Zukin RS (2007). NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 8: 413-426
162. Law AJ, Weickert CS, Hyde TM, Kleinman JE, Harrison PJ (2004). Reduced spinophilin but not microtubule-Associated protein 2 expression in the hippocampal formation in schizophrenia and mood disorders: Molecular evidence for a pathology of dendritic spines. Am J Psychiatry 161: 1848-1855
163. Le Corre S, Harper CG, Lopez P, Ward P, Catts S (2000). Increased levels of expression of an NMDARI splice variant in the superior temporal gyrus in schizophrenia. Neuroreport 11: 983-986
164. Le Greves M, Zhou Q, Berg M, Le Greves P, Fholenhag K, Meyerson B et al. (2006). Growth hormone replacement in hypophysectomized rats affects spatial performance and hippocampal levels of NMDA receptor subunit and PSD-95 gene transcript levels. Exp Brain Res 173: 267-273
165. Lee FJ, Pei L, Liu F (2009). Disruption of the dopamine transporter-dopamine D2 receptor interaction in schizophrenia. Synapse 63: 710-712
166. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI (2005). Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 30: 1883-1894
167. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI (2007). Prenatal stress generates deficits in rat social behavior: Reversal by oxytocin. Brain Res 1156: 152-167
168. Leonard AS, Davare MA, Horne MC, Garner CC, Hell JW (1998). SAP97 is associated with the alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit. J Biol Chem 273: 19518-19524
169. Leonard S, Logel J, Luthman D, Casanova M, Kirch D, Freedman R (1993). Biological stability of mRNA isolated from human postmortem brain collections. Biol Psychiatry 33: 456-466
170. Lepage M, Montoya A, Pelletier M, Achim AM, Menear M, Lal S (2006). Associative memory encoding and recognition in schizophrenia: An event-related fMRI study. Biol Psychiatry 60: 1215-1223
171. Levinson DF, Shi J, Wang K, Oh S, Riley B, Pulver AE et al. (2012). Genome-wide association study of multiplex schizophrenia pedigrees. Am J Psychiatry 169: 963-973
172. Lewis DA, Volk DW, Hashimoto T (2004). Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: A novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174: 143-150
173. Li J, Gould TD, Yuan P, Manji HK, Chen G (2003). Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology 28: 1017-1025
174. Li JZ, Vawter MP, Walsh DM, Tomita H, Evans SJ, Choudary PV et al. (2004). Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 13: 609-616
175. Li X, Friedman AB, Roh M-S, Jope RS (2005). Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain. J Neurochem 92: 701-704
176. Li X, Greenwood AF, Powers R, Jope RS (1996). Effects of postmortem interval, age, and Alzheimer's disease on G-proteins in human brain. Neurobiol Aging 17: 115-122
177. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223
178. Lijam N, Paylor R, McDonald MP, Crawley JN, Deng CX, Herrup K et al. (1997). Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. Cell 90: 895-905
179. Lionel AC, Vaags AK, Sato D, Gazzellone MJ, Mitchell EB, Chen HY et al. (2013). Rare exonic deletions implicate the synaptic organizer Gephyrin (GPHN) in risk for autism, schizophrenia and seizures. Hum Mol Genet 22: 2055-2066
180. Lipska BK, Deep-Soboslay A, Weickert CS, Hyde TM, Martin CE, Herman MM et al. (2006a). Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. Biol Psychiatry 60: 650-658
181. Lipska BK, Peters T, Hyde TM, Halim N, Horowitz C, Mitkus S et al. (2006b). Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum Mol Genet 15: 1245-1258
182. Lisman JE, Zhabotinsky AM (2001). A model of synaptic memory: A CaMKII/PP1 switch that potentiates transmission by organizing an AMPA receptor anchoring assembly. Neuron 31: 191-201
183. Ma TM, Abazyan S, Abazyan B, Nomura J, Yang C, Seshadri S et al. (2013). Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenialike behavior via D-serine depletion. Mol Psychiatry 18: 557-567
184. MacDonald ML, Ciccimaro E, Prakash A, Banerjee A, Seeholzer SH, Blair IA et al. (2012). Biochemical fractionation and stable isotope dilution liquid chromatography-mass spectrometry for targeted and microdomain-specific protein quantification in human postmortem brain tissue. Mol Cell Proteomics 11: 1670-1681
185. Malenka RC, Nicoll RA (1999). Long-Term potentiation-A decade of progress? Science 285: 1870-1874
186. Marballi K, Cruz D, Thompson P, Walss-Bass C (2012). Differential neuregulin 1 cleavage in the prefrontal cortex and hippocampus in schizophrenia and bipolar disorder: Preliminary findings. PLoS One 7: E36431
187. Marballi K, Quinones MP, Jimenez F, Escamilla MA, Raventos H, Soto-Bernardini MC et al. (2010). In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation. J Mol Med (Berl) 88: 1133-1141
188. Marenco S, Weinberger DR (2000). The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave. Dev Psychopathol 12: 501-527
189. McCullumsmith R, Clinton S, Meador-Woodruff J (2004). Schizophrenia as a disorder of neuroplasticity. Int Rev Neurobiol 59: 19-45
190. McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH (2007). Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 1127: 108-118
191. McCullumsmith RE, Meador-Woodruff JH (2002). Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 26: 368-375
192. McCullumsmith RE, Meador-Woodruff JH (2011). Novel approaches to the study of postmortem brain in psychiatric illness: Old limitations and new challenges. Biol Psychiatry 69: 127-133
193. McGee AW, Bredt DS (2003). Assembly and plasticity of the glutamatergic postsynaptic specialization. Curr Opin Neurobiol 13: 111-118
194. Meador-Woodruff J, Clinton S, Beneyto M, McCullumsmith R (2003). Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Ann NY Acad Sci 1003: 75-93
195. Meador-Woodruff JH, Hogg AJ Jr., Smith RE (2001). Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 55: 631-640
196. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M et al. (2005). The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 80: 9-18
197. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P (2002). Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22: 2718-2729
198. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA et al. (2000). Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 9: 1415-1423
199. Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R et al. (1994). c-Jun N-Terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-Activated protein kinases. Mol Cell Biol 14: 6683-6688
200. Miner LA, Ostrander M, Sarter M (1997). Effects of ibotenic acid-induced loss of neurons in the medial prefrontal cortex of rats on behavioral vigilance: Evidence for executive dysfunction. J Psychopharmacol 11: 169-178
201. Mirnics K, Middleton F, Marquez A, Lewis D, Levitt P (2000). Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28: 53-67
202. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427-436
203. Morciano M, Burre J, Corvey C, Karas M, Zimmermann H, Volknandt W (2005). Immunoisolation of two synaptic vesicle pools from synaptosomes: A proteomics analysis. J Neurochem 95: 1732-1745
204. Morrow JA, Maclean JKF, Jamieson C (2012). AMPA Receptor Positive ModulatorsAlbert JS, Wood MWTargets and Emerging Therapies for Schizophrenia. John Wiley & Sons: Hoboken, NJ, USA187-218
205. Müller BM, Kistner U, Veh RW, Cases-Langhoff C, Becker B, Gundelfinger ED et al. (1995). Molecular characterization and spatial distribution of SAP97, a novel presynaptic protein homologous to SAP90 and the Drosophila discs-large tumor suppressor protein. J Neurosci 15: 2354-2366
206. Nagai T, Kitahara Y, Ibi D, Nabeshima T, Sawa A, Yamada K (2011). Effects of antipsychotics on the behavioral deficits in human dominant-negative DISC1 transgenic mice with neonatal polyI:C treatment. Behav Brain Res 225: 305-310
207. O'Neill RA, Bhamidipati A, Bi X, Deb-Basu D, Cahill L, Ferrante J et al. (2006). Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc Natl Acad Sci USA 103: 16153-16158
208. O'Callaghan JP, Sriram K (2004). Focused microwave irradiation of the brain preserves in vivo protein phosphorylation: Comparison with other methods of sacrifice and analysis of multiple phosphoproteins. J Neurosci Methods 135: 159-168
209. Ohnuma T, Kato H, Arai H, Faull RL, McKenna PJ, Emson PC (2000). Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 11: 3133-3137
210. Oka T, Tagawa K, Ito H, Okazawa H (2011). Dynamic changes of the phosphoproteome in postmortem mouse brains. PLoS One 6: E21405
211. Oni-Orisan A, Kristiansen L, Haroutunian V, Meador-Woodruff J, McCullumsmith R (2008). Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol Psychiatry 63: 766-775
212. Oni-Orisan A, Kristiansen LV, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE (2008). Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol Psychiatry 63: 766-775
213. Pan L, Wu H, Shen C, Shi Y, Jin W, Xia J et al. (2007). Clustering and synaptic targeting of PICK1 requires direct interaction between the PDZ domain and lipid membranes. EMBO J 26: 4576-4587
214. Pardue S, Zimmerman AL, Morrison-Bogorad M (1994). Selective postmortem degradation of inducible heat shock protein 70 (hsp70) mRNAs in rat brain. Cell Mol Neurobiol 14: 341-357
215. Parkin ET, Hussain I, Karran EH, Turner AJ, Hooper NM (1999). Characterization of detergent-insoluble complexes containing the familial Alzheimer's diseaseassociated presenilins. J Neurochem 72: 1534-1543
216. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM et al. (2008). Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 13: 1102-1117
217. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977). Neurotransmitter enzyme abnormalities in senile dementia: Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34: 247-265
218. Pierri JN, Volk CL, Auh S, Sampson A, Lewis DA (2001). Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry 58: 466-473
219. Piette MA, Pieters SP, Letter E (2011). Evaluation of the agonal stress: Can immunohistochemical detection of ubiquitin in the locus coeruleus be useful? Int J Legal Med 125: 333-340
220. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL et al. (2004). Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9: 684-697. 643
221. Rea TD (2005). Agonal respirations during cardiac arrest. Curr Opin Crit Care 11: 188-191
222. Roberts RC (2007). Schizophrenia in translation: Disrupted in schizophrenia (DISC1): Integrating clinical and basic findings. Schizophr Bull 33: 11-15
223. Rubio MD, Haroutunian V, Meador-Woodruff JH (2012). Abnormalities of the Duo/ Ras-related C3 botulinum toxin substrate 1/p21-Activated kinase 1 pathway drive myosin light chain phosphorylation in frontal cortex in schizophrenia. Biol Psychiatry 71: 906-914
224. Rumbaugh G, Sia G, Garner C, Huganir R (2003). Synapse-Associated protein-97 isoform-specific regulation of surface AMPA receptors and synaptic function in cultured neurons. J Neurosci 23: 4567-4576
225. Ruzicka WB, Zhubi A, Veldic M, Grayson DR, Costa E, Guidotti A (2007). Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-Assisted microdissection. Mol Psychiatry 12: 385-397
226. Sawamura N, Sawamura-Yamamoto T, Ozeki Y, Ross CA, Sawa A (2005). A form of DISC1 enriched in nucleus: Altered subcellular distribution in orbitofrontal cortex in psychosis and substance/alcohol abuse. Proc Natl Acad Sci USA 102: 1187-1192
227. Schmitt A, Hasan A, Gruber O, Falkai P (2011). Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci 261(Suppl 2): S150-S154
228. Scott DB, Blanpied TA, Ehlers MD (2003). Coordinated PKA and PKC phosphorylation suppresses RXR-mediated ER retention and regulates the surface delivery of NMDA receptors. Neuropharmacology 45: 755-767
229. Shan D, Yates SD, Roberts RC, McCullumsmith RE (2013). Update on the neurobiology of schizophrenia: A role for extracellular microdomains. Minerva Psichiatrica 53: 233-249
230. Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW et al. (2009). Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res 69: 5987-5995
231. Smith MJ, Sharples RA, Evin G, McLean CA, Dean B, Pavey G et al. (2004). Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. Brain Res Mol Brain Res 127: 128-135
232. Smoller JW, Craddock N, Kendler K, Lee PH, Neale BM, Nurnberger JI et al. (2013). Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet 381: 1371-1379
233. Sodhi MS, Simmons M, McCullumsmith R, Haroutunian V, Meador-Woodruff JH (2011). Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia. Biol Psychiatry 70: 646-654
234. Sokolov B (1998). Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: Evidence on reversible up-regulation by typical neuroleptics. J Neurochem 71: 2454-2464
235. Spokes EGS, Garrett NJ, Iversen LL (1979). Differential effects of agonal status on measurements of gaba and glutamate decarboxylase in human post-mortem brain tissue from control and Huntington's chorea subjects. J Neurochem 33: 773-778
236. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ et al. (2006). Human postmortem tissue: What quality markers matter? Brain Res 1123: 1-11
237. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71: 877-892
238. Stockmeier CA (1997). Neurobiology of serotonin in depression and suicide. Ann NY Acad Sci 836: 220-232
239. Swatton JE, Sellers LA, Faull RL, Holland A, Iritani S, Bahn S (2004). Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur J Neurosci 19: 2711-2719
240. Szeszko PR, Hodgkinson CA, Robinson DG, Derosse P, Bilder RM, Lencz T et al. (2008). DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol 79: 103-110
241. Szumlinski KK, Lominac KD, Kleschen MJ, Oleson EB, Dehoff MH, Schwarz MK et al. (2005). Behavioral and neurochemical phenotyping of Homer1 mutant mice: Possible relevance to schizophrenia. Genes Brain Behav 4: 273-288
242. Takahashi N, Nielsen KS, Aleksic B, Petersen S, Ikeda M, Kushima I et al. (2011). Loss of function studies in mice and genetic association link receptor protein tyrosine phosphatase alpha to schizophrenia. Biol Psychiatry 70: 626-635
243. Takahashi T, Suzuki M, Tsunoda M, Maeno N, Kawasaki Y, Zhou SY et al. (2009). The Disrupted-in-Schizophrenia-1 Ser704Cys polymorphism and brain morphology in schizophrenia. Psychiatry Res 172: 128-135
244. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ et al. (2004). Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113: 1353-1363
245. Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N (1990). Neurolepticinduced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains. Psychopharmacology (Berl) 102: 474-478
246. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM (1994). Clozapine in tardive dyskinesia: Observations from human and animal model studies. J Clin Psychiatry 55(Suppl B): 102-106
247. Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, Li J et al. (2004a). Effect of agonal and postmortem factors on gene expression profile: Quality control in microarray analyses of postmortem human brain. Biol Psychiatry 55: 346-352
248. Tomita Y, Nihira M, Ohno Y, Sato S (2004b). Ultrastructural changes during in situ early postmortem autolysis in kidney, pancreas, liver, heart and skeletal muscle of rats. Leg Med (Tokyo) 6: 25-31
249. Toro C, Deakin JF (2005). NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 80: 323-330
250. Toyooka K, Iritani S, Makifuchi T, Shirakawa O, Kitamura N, Maeda K et al. (2002a). Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J Neurochem 83: 797-806
251. Toyooka K, Usui M, Washiyama K, Kumanishi T, Takahashi Y (2002b). Gene expression profiles in the brain from phencyclidine-Treated mouse by using DNA microarray. Ann NY Acad Sci 965: 10-20
252. Trinh JV, Nehrenberg DL, Jacobsen JP, Caron MG, Wetsel WC (2003). Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience 118: 297-310
253. Trotter SA, Brill LB 2nd, Bennett JP Jr. (2002). Stability of gene expression in postmortem brain revealed by cDNA gene array analysis. Brain Res 942: 120-123
254. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE et al. (1995). Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52: 829-836
255. Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS et al. (2004). Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype. Proc Natl Acad Sci USA 101: 8485-8490
256. Tucholski J, Simmons MS, Pinner AL, Haroutunian V, McCullumsmith RE, Meador-Woodruff JH (2013). Abnormal N-linked glycosylation of cortical AMPA receptor subunits in schizophrenia. Schizophr Res 146: 177-183
257. Tuominen H, Tiihonen J, Wahlbeck K (2005). Glutamatergic drugs for schizophrenia: A systematic review and meta-Analysis. Schizophr Res 72: 225-234
258. Tuominen H, Tiihonen J, Wahlbeck K (2006). Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev 2: 1-40
259. Uezato A, Meador-Woodruff JH, McCullumsmith RE (2009). Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia. Bipolar Disord 11: 711-725
260. Valtschanoff JG, Burette A, Davare MA, Leonard AS, Hell JW, Weinberg RJ (2000). SAP97 concentrates at the postsynaptic density in cerebral cortex. Eur J Neurosci 12: 3605-3614
261. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH 3rd, Donovan DM et al. (2001). Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 55: 641-650
262. Vawter MP, Tomita H, Meng F, Bolstad B, Li J, Evans S et al. (2006). Mitochondrialrelated gene expression changes are sensitive to agonal-pH state: Implications for brain disorders. Mol Psychiatry 11: 663-679
263. Walss-Bass C, Liu W, Lew DF, Villegas R, Montero P, Dassori A et al. (2006). A novel missense mutation in the transmembrane domain of neuregulin 1 is associated with schizophrenia. Biol Psychiatry 60: 548-553
264. Webster MJ (2006). Tissue preparation and banking. Prog Brain Res 158: 3-14
265. Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, Garrick T et al. (2010). Selection of reference gene expression in a schizophrenia brain cohort. Aust NZ J Psychiatry 44: 59-70
266. Weickert CS, Straub RE, McClintock BW, Matsumoto M, Hashimoto R, Hyde TM et al. (2004). Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 61: 544-555
267. Weiss IC, Di Iorio L, Feldon J, Domeney AM (2000). Strain differences in the isolation-induced effects on prepulse inhibition of the acoustic startle response and on locomotor activity. Behav Neurosci 114: 364-373
268. Wezenberg E, Verkes R, Ruigt G, Hulstijn W, Sabbe B (2007). Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology 32: 1272-1283
269. Whittaker VP, Michaelson IA, Kirkland RJ (1963). The separation of synaptic vesicles from disrupted nervending particles. Biochem Pharmacol 12: 300-302
270. Wible CG, Preus AP, Hashimoto R (2009). A cognitive neuroscience view of schizophrenic symptoms: Abnormal activation of a system for social perception and communication. Brain Imaging Behav 3: 85-110
271. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M et al. (2005). The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66: 1122-1129
272. Yao W-D, Gainetdinov RR, Arbuckle MI, Sotnikova TD, Cyr M, Beaulieu J-M et al. (2004). Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron 41: 625-638
273. Yee BK, Keist R, von Boehmer L, Studer R, Benke D, Hagenbuch N et al. (2005). A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction. Proc Natl Acad Sci USA 102: 17154-17159
274. Yoo BC, Seidl R, Cairns N, Lubec G (1999). Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer's disease. J Neural Transm Suppl 57: 315-322
275. Zhang L, Daly RJ (2012). Targeting the human kinome for cancer therapy: Current perspectives. Crit Rev Oncog 17: 233-246
276. Zhang Q, Fan J, Zhang M (2001). Interdomain chaperoning between PSD-95, Dlg, and Zo-1 (PDZ) domains of glutamate receptor-interacting proteins. J Biol Chem 276: 43216-43220